17 apr: Europa/luk: Finanssektoren trak kraftigt op
18 apr: USA/aktier: Største stigninger i en måned
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
02 maj - 
Aktier/åbning: Danske Bank løftes af norsk storbank ..
02 maj - 
Aktier/tendens: Maj ser ud til at starte godt for Dansk..
29 apr - 
Vestas og Danske Bank scorer 11 mia. efter regnskaber ..
Relateret debat
04 maj - 
hold da op det har du godt nok sagt længe efterh&..
04 maj - 
Det hedder interval træning, meget effektivt.
04 maj - 
Ganske enkel fordi de den er for dyr på nøgletal. Med e..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
04 maj
NOVO-B
Lad os tage Fremtidige produkter (pipeline) i alfabetisk orden:   Fiasp godkendes ultimo 2016 i USA ..
17
29 apr
NOVO-B
  Til ReneeB,   Som skrevet i går, kunne jeg desværre ikke vise dig Notaer for mine handler i NOVO..
5
28 apr
NOVO-B
Bagsværd, Denmark, 28 April 2016 - Novo Nordisk today announced the top-line results from the sixth ..
5
04 maj
NOVO-B
det er omkring 99 meter for langt for ham, for han forstaar ikke en meter
4
04 maj
NOVO-B
Det har INTET med alpehue at gøre ? Øgenavne og den slags tegninger hører altså ikke hjemme i en deb..
4
28 apr
NOVO-B
De skal levere nyheden til markedet når de kender den. Før/efter/under regnskabsaflæggelse har intet..
4
28 apr
NOVO-B
Nå - det kan være jeg skal trække mine udsagn tilbage fra i morges :)
4
04 maj
NOVO-B
Ufatteligt EI giver dig lov til det der !!!!
3
04 maj
NOVO-B
Vi har jo hver især vores Strategi og handlesmetoder der virker for os. Og sådan er det bare !!   Je..
3
30 apr
NOVO-B
Novo er simpelthen fuld af fup og fidus.... det er nemlig en af grundene til at FDA ligefrem bad og ..
3

Vestas får ordre på 178 MW til Kansas

04-05-2016 13:34:31
54 Vestas-møller skal i løbet af det næste år op at stå i vindblæste Kansas i USA.Capital Power Corporation har bestilt møllerne til Boom Wind-projektet, som få..

Aktier/åbning: Mærsk hiver C20 op på tung regnskabsmorgen- KORR

04-05-2016 09:31:23
KORR: Overskrift rettet til "åbning"En sand regnskabsstorm ramte investorerne fra morgenstunden, hvor blandt andet A.P. Møller-Mærsk, TDC, ISS, GN Store Nord, N..

Mærsk Q1: Tilbagegang mindre end frygtet

04-05-2016 08:19:18
Tilbagegangen i A.P. Møller-Mærsk var i årets første kvartal mindre, end analytikerne havde spået.Årets indledende tre måneder bød på en tilbagegang i omsætning..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Mærsk vejer tungt på vild regnskabsdag
2
Vestas får ordre på 178 MW til Kansas
3
Aktier/åbning: Mærsk hiver C20 op på tung regnskabsmorgen- KORR
4
Dantherm understreger konkursrisiko efter stor stigning
5
Mærsk/MS: Langt op til markedets mål resten af året

Relaterede aktiekurser

Novo Nordisk B A/S 349,50 -1,2% Fald i aktiekurs
Novo-Nordisk A/S 53,79 -1,7% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
5. maj 2016 04:52:44
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160502.2 - EUROWEB7 - 2016-05-05 04:52:44 - 2016-05-05 04:52:44 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x